MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Roivant Sciences Ltd

Suletud

SektorTervishoid

11.42 -1.89

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.38

Max

11.7

Põhinäitajad

By Trading Economics

Sissetulek

-278M

-252M

Müük

-1.4M

7.6M

Aktsiakasum

-0.29

Kasumimarginaal

-3,333.884

Töötajad

750

EBITDA

-9.2M

-284M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+38.65% upside

Turustatistika

By TradingEconomics

Turukapital

313M

7.9B

Eelmine avamishind

13.31

Eelmine sulgemishind

11.42

Uudiste sentiment

By Acuity

50%

50%

169 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Roivant Sciences Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuli 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17. juuli 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17. juuli 2025, 21:04 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17. juuli 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17. juuli 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:30 UTC

Market Talk
Tulu

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17. juuli 2025, 22:04 UTC

Market Talk
Tulu

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17. juuli 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17. juuli 2025, 21:58 UTC

Market Talk
Tulu

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17. juuli 2025, 21:57 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:47 UTC

Tulu

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17. juuli 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. juuli 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17. juuli 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17. juuli 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 21:05 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:04 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17. juuli 2025, 21:02 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

17. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Roivant Sciences Ltd Prognoos

Hinnasiht

By TipRanks

38.65% tõus

12 kuu keskmine prognoos

Keskmine 16 USD  38.65%

Kõrge 19 USD

Madal 12 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Roivant Sciences Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

11 / 11.18Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

169 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.